QIAGEN N.V./$QGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About QIAGEN N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
Ticker
$QGEN
Sector
Primary listing
NYSE
Employees
5,500
Headquarters
Website
QIAGEN N.V. Metrics
BasicAdvanced
$7.3bn
18.32
$1.94
0.64
$0.25
0.70%
Price and volume
Market cap
$7.3bn
Beta
0.64
52-week high
$57.82
52-week low
$32.53
Average daily volume
2.3m
Dividend rate
$0.25
Financial strength
Current ratio
3.215
Quick ratio
2.177
Long term debt to equity
49.421
Total debt to equity
49.421
Dividend payout ratio (TTM)
13.49%
Interest coverage (TTM)
14.71%
Profitability
EBITDA (TTM)
727.685
Gross margin (TTM)
66.00%
Net profit margin (TTM)
19.16%
Operating margin (TTM)
25.80%
Effective tax rate (TTM)
11.91%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
6.01%
Return on equity (TTM)
11.93%
Valuation
Price to earnings (TTM)
18.319
Price to revenue (TTM)
3.493
Price to book
2.2
Price to tangible book (TTM)
27.33
Price to free cash flow (TTM)
18.149
Free cash flow yield (TTM)
5.51%
Free cash flow per share (TTM)
1.958
Dividend yield (TTM)
0.70%
Forward dividend yield
0.70%
Growth
Revenue change (TTM)
4.79%
Earnings per share change (TTM)
338.22%
3-year revenue growth (CAGR)
1.65%
10-year revenue growth (CAGR)
5.06%
3-year earnings per share growth (CAGR)
4.12%
10-year earnings per share growth (CAGR)
11.98%
QIAGEN N.V. News
AllArticlesVideos
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
Business Wire·1 week ago
QGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.
Business Wire·1 week ago
QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs